﻿{"id":1394,"date":"2026-09-30T23:40:20","date_gmt":"2026-09-30T18:10:20","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/?p=1394"},"modified":"2026-09-30T23:40:20","modified_gmt":"2026-09-30T18:10:20","slug":"sunpharma-final-approval-sample-1061","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-final-approval-sample-1061\/","title":{"rendered":"Sun Pharma Final Approval Sample \u2013 Draft 1061 Structure"},"content":{"rendered":"<div data-test-layout=\"v5\">\n<div style=\"display:flex;flex-wrap:wrap;gap:7px;margin:8px 0 14px;\">\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Price<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,821.30<\/div>\n<\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Change<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\"><span style='color:#b42318;'>-2.34%<\/span><\/div>\n<\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">High \/ Low<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,860.60 \/ \u20b91,814.20<\/div>\n<\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Prev. Close<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,865.00<\/div>\n<\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Volume<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">6.10L<\/div>\n<\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"font-size:9px;text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Updated<\/div>\n<div style=\"font-size:13px;font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">11:25 AM<\/div>\n<\/div>\n<\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:4px solid #2e7db2;border-radius:10px;padding:13px 15px;margin:12px 0 18px;\">\n<div style=\"font-size:15px;font-weight:900;color:#1f4d70;margin-bottom:6px;\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;line-height:1.55;font-size:13.5px;\">\n<li>Sun Pharma was trading <strong>2.34% lower<\/strong> at \u20b91,821.30 and close to the lower end of the session range.<\/li>\n<li>Recent strategic news includes the lerodalcibep licensing agreement and a reported plan to raise about \u20b9100 billion in domestic bonds to refinance part of the Organon bridge loan.<\/li>\n<li>By 11:25 AM, cash volume was around <strong>44% of the 20-day average full-session volume<\/strong>, so the fall was not accompanied by unusually heavy cash turnover.<\/li>\n<\/ul>\n<\/div>\n<h2>Why Sun Pharma Shares Are Falling 2.3% Today<\/h2>\n<p style=\"line-height:1.67;font-size:13.5px;\">Sun Pharma slipped to \u20b91,821.30 by 11:25 AM, down 2.34% from the previous close of \u20b91,865.00. The stock opened at \u20b91,860.60, touched a low of \u20b91,814.20 and remained close to the lower end of the day\u2019s range, indicating that selling pressure had persisted through the morning.<\/p>\n<p style=\"line-height:1.67;font-size:13.5px;\">The company has important recent news, but it is not obviously negative enough to explain the decline on its own. Sun Pharma signed an exclusive licensing agreement for lerodalcibep outside the US and China, expanding its innovative-medicines portfolio. Separately, a roughly \u20b9100 billion domestic bond issue is being planned to refinance part of the bridge loan used for the Organon acquisition. These are material strategic developments, but the available evidence does not establish either as the direct trigger for the 2.3% fall.<\/p>\n<p style=\"line-height:1.67;font-size:13.5px;\">Trading activity also does not look unusually heavy. About 6.10 lakh shares had changed hands by 11:25 AM versus a 20-session average full-day volume of about 13.85 lakh shares, or roughly 44% of the average session. That is meaningful participation, but not the kind of cash-volume pace that by itself points to an aggressive sell-off. At this stage, the decline looks more like sustained price weakness with moderate market participation rather than a volume-led breakdown.<\/p>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:14px 16px;margin:15px 0 20px;\">\n<div style=\"font-size:15px;font-weight:900;color:#174c5d;margin-bottom:6px;\">Likely Reason for Today&#8217;s Move<\/div>\n<div style=\"font-size:16px;font-weight:850;color:#20384a;margin-bottom:6px;\">Broader pharma\/stock weakness rather than one negative company trigger<\/div>\n<div style=\"line-height:1.58;font-size:13.5px;\">Sun Pharma is trading near the lower end of the intraday range, while the cash-volume pace remains moderate rather than extreme. Recent company developments are strategically important but do not provide a clear negative explanation for the fall.<\/div>\n<ul style=\"margin:8px 0 0;padding-left:18px;line-height:1.5;font-size:13px;\">\n<li>Price near session low: \u20b91,821.30 vs \u20b91,814.20<\/li>\n<li>Cash volume by 11:25 AM: ~44% of 20-day average full-session volume<\/li>\n<li>Cash-market volume pace remains below an average full session<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:linear-gradient(135deg,#ffe873,#ffd64a);border:1px solid #e3b600;border-radius:13px;padding:18px 19px;margin:21px 0;box-shadow:0 8px 18px rgba(59,48,0,.09);\">\n<div style=\"font-size:19px;font-weight:950;color:#10233f;margin-bottom:5px;\">Research the Market \u2014 Not Just the Headline<\/div>\n<div style=\"font-size:13px;line-height:1.55;color:#27364b;margin-bottom:12px;\">Get data-backed stock, F&amp;O and options research from a SEBI Registered Research Analyst.<\/div>\n<p><a href=\"https:\/\/www.wittytrades.com\/Segments.html\" style=\"display:inline-block;background:#10233f;color:#fff;text-decoration:none;font-weight:900;padding:10px 17px;border-radius:7px;\">Explore WittyTrades Research \u2192<\/a><\/div>\n<h2>Latest Company Developments<\/h2>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(225px,1fr));gap:10px;margin:10px 0 22px;\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-size:14px;font-weight:900;color:#17324d;line-height:1.35;\">Lerodalcibep Licensing Agreement<\/div>\n<div style=\"font-size:10.5px;color:#708090;margin:3px 0 6px;\">28 Sep 2026<\/div>\n<div style=\"line-height:1.5;font-size:12.5px;color:#34495d;\">Sun Pharma secured rights to manufacture and commercialise lerodalcibep globally outside the US and China, expanding its cardiovascular specialty portfolio.<\/div>\n<\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-size:14px;font-weight:900;color:#17324d;line-height:1.35;\">Domestic Debt Refinancing Plan<\/div>\n<div style=\"font-size:10.5px;color:#708090;margin:3px 0 6px;\">29 Sep 2026<\/div>\n<div style=\"line-height:1.5;font-size:12.5px;color:#34495d;\">A roughly \u20b9100 billion domestic bond issue is planned to refinance part of the bridge loan used for the Organon acquisition.<\/div>\n<\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-size:14px;font-weight:900;color:#17324d;line-height:1.35;\">US Pricing \/ Access Development<\/div>\n<div style=\"font-size:10.5px;color:#708090;margin:3px 0 6px;\">Sep 2026<\/div>\n<div style=\"line-height:1.5;font-size:12.5px;color:#34495d;\">Recent US policy and pricing developments remain relevant for Sun Pharma\u2019s specialty portfolio and overseas earnings outlook.<\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(275px,1fr));gap:12px;margin:11px 0 22px;\">\n<div style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:14px 15px;min-width:0;\">\n<div style=\"font-size:15px;font-weight:900;color:#8c6318;margin-bottom:9px;\">Promoter Pledge \/ Encumbrance<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:7px;\">\n<div style=\"background:#fffdf7;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Promoter Holding<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">54.48%<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">No q\/q change<\/div>\n<\/div>\n<div style=\"background:#fffdf7;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Pledged<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">1.65%<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">Of promoter holding<\/div>\n<\/div>\n<div style=\"background:#fffdf7;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Pledge Change<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">+0.23 pp<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">Latest quarter<\/div>\n<\/div>\n<div style=\"background:#fffdf7;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Pledged Shares<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">21.52M<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">Latest available<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:14px 15px;min-width:0;\">\n<div style=\"font-size:15px;font-weight:900;color:#405d76;margin-bottom:9px;\">Recent Ownership \/ Shareholding<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">FII\/FPI<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">14.54%<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">15.94% previous qtr<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Mutual Funds<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">12.84%<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">11.96% previous qtr<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">Institutional<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">36.71%<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">37.05% previous qtr<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"font-size:9.5px;text-transform:uppercase;color:#74808d;font-weight:800;\">MF Schemes<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:3px;\">49<\/div>\n<div style=\"font-size:10px;color:#71808d;margin-top:2px;\">47 previous qtr<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Activity<\/h2>\n<div style=\"border:1px solid #d5e0ea;border-radius:11px;background:#f7f9fc;padding:14px 15px;margin:10px 0 22px;\">\n<div style=\"font-size:13px;line-height:1.55;color:#34495d;margin-bottom:10px;\">Mutual funds increased their aggregate stake to 12.84% in Jun 2026, with the number of schemes also rising. The largest disclosed fund positions are shown below.<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(145px,1fr));gap:8px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:11.5px;font-weight:850;color:#20384a;line-height:1.35;\">ICICI Prudential Value Fund<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:4px;\">89.20M shares<\/div>\n<div style=\"font-size:10.5px;color:#74808d;margin-top:2px;\">Jun 2026<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:11.5px;font-weight:850;color:#20384a;line-height:1.35;\">SBI Nifty 50 ETF<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:4px;\">56.69M shares<\/div>\n<div style=\"font-size:10.5px;color:#74808d;margin-top:2px;\">Jun 2026<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:11.5px;font-weight:850;color:#20384a;line-height:1.35;\">Nippon India Large Cap Fund<\/div>\n<div style=\"font-size:14px;font-weight:950;color:#17324d;margin-top:4px;\">33.13M shares<\/div>\n<div style=\"font-size:10.5px;color:#74808d;margin-top:2px;\">Jun 2026<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Recent Brokerage Views<\/h2>\n<div style=\"border:1px solid #cbd8ea;border-radius:11px;background:#f4f8fd;padding:13px 14px;margin:10px 0 22px;\">\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(175px,1fr));gap:8px;\">\n<div style=\"background:#fff;border:1px solid #dfe7f0;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:12px;font-weight:900;color:#21384f;\">Deven Choksey<\/div>\n<div style=\"font-size:12px;margin-top:4px;\"><strong>Accumulate<\/strong> \u2022 Target \u20b92,218<\/div>\n<div style=\"font-size:10.5px;color:#74808d;margin-top:2px;\">04 Aug 2026<\/div>\n<div style=\"font-size:11px;color:#536273;margin-top:5px;line-height:1.4;\">Cited strength in India formulations, specialty products and innovation.<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #dfe7f0;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:12px;font-weight:900;color:#21384f;\">Motilal Oswal<\/div>\n<div style=\"font-size:12px;margin-top:4px;\"><strong>Buy<\/strong> \u2022 Target \u20b92,310<\/div>\n<div style=\"font-size:10.5px;color:#74808d;margin-top:2px;\">01 Aug 2026<\/div>\n<div style=\"font-size:11px;color:#536273;margin-top:5px;line-height:1.4;\">Highlighted specialty and branded businesses after the quarterly update.<\/div>\n<\/div>\n<\/div>\n<div style=\"font-size:10.5px;color:#6d7885;margin-top:8px;\">Third-party brokerage opinions; not WittyTrades recommendations.<\/div>\n<\/div>\n<h2>Recent Bulk \/ Block Deal Activity<\/h2>\n<div style=\"border:1px solid #ead4c0;border-radius:11px;background:#fff8f2;padding:13px 14px;margin:10px 0 22px;\">\n<div style=\"font-size:12.5px;color:#5b4c40;line-height:1.5;margin-bottom:9px;\">Sun Pharma has several disclosed block transactions within the trailing 12 months.<\/div>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(180px,1fr));gap:8px;\">\n<div style=\"background:#fff;border:1px solid #eadfd4;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:10px;color:#7b6b5c;font-weight:800;\">24 Jun 2026 \u2022 Block<\/div>\n<div style=\"font-size:11.5px;font-weight:850;color:#493c32;margin-top:4px;line-height:1.35;\">MTBJ \/ Government Pension Investment Fund accounts<\/div>\n<div style=\"font-size:12px;color:#493c32;margin-top:5px;\"><strong>154,424 shares<\/strong> \u2022 \u20b91,868<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #eadfd4;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:10px;color:#7b6b5c;font-weight:800;\">18 Nov 2025 \u2022 Block<\/div>\n<div style=\"font-size:11.5px;font-weight:850;color:#493c32;margin-top:4px;line-height:1.35;\">GQG Partners \/ Reliance Trust<\/div>\n<div style=\"font-size:12px;color:#493c32;margin-top:5px;\"><strong>1,446,414 shares<\/strong> \u2022 \u20b91,763.90<\/div>\n<\/div>\n<div style=\"background:#fff;border:1px solid #eadfd4;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-size:10px;color:#7b6b5c;font-weight:800;\">09 Oct 2025 \u2022 Block<\/div>\n<div style=\"font-size:11.5px;font-weight:850;color:#493c32;margin-top:4px;line-height:1.35;\">Goldman Sachs Bank Europe \/ Goldman Sachs Singapore<\/div>\n<div style=\"font-size:12px;color:#493c32;margin-top:5px;\"><strong>148,233 shares<\/strong> \u2022 \u20b91,631.60<\/div>\n<\/div>\n<\/div>\n<div style=\"font-size:10.5px;color:#7b6b5c;margin-top:8px;\">Large transactions provide ownership\/liquidity context and are not directional signals on their own.<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul style=\"line-height:1.6;font-size:13.5px;\">\n<li>Whether Sun Pharma stabilises above the \u20b91,814 intraday low.<\/li>\n<li>Whether cash volume accelerates significantly from the current 44%-of-average pace.<\/li>\n<li>Details of the Organon refinancing and commercial rollout of lerodalcibep.<\/li>\n<\/ul>\n<div style=\"background:#10233f;border-radius:13px;padding:19px 21px;margin:25px 0;box-shadow:0 9px 22px rgba(16,35,63,.18);\">\n<div style=\"font-size:19px;font-weight:900;color:#fff;margin-bottom:5px;\">Looking for Research-Backed Market Opportunities?<\/div>\n<div style=\"font-size:13px;line-height:1.55;color:#dce6f1;margin-bottom:12px;\">Move beyond generic charts with structured research across price action, derivatives, company developments and market activity.<\/div>\n<p><a href=\"https:\/\/www.wittytrades.com\/Segments.html\" style=\"display:inline-block;background:#ffe36e;color:#10233f;text-decoration:none;font-weight:900;padding:10px 17px;border-radius:7px;\">View Research Segments \u2192<\/a><\/div>\n<h2>Frequently Asked Questions<\/h2>\n<h3 style=\"margin:13px 0 4px;font-size:15px;\">Why is Sun Pharma share price falling today?<\/h3>\n<p style=\"margin:0;line-height:1.55;font-size:13px;\">The stock is weak near the session low, but there is no single confirmed negative company trigger. Cash-market participation is meaningful but not unusually heavy, so the fall currently looks more like broader stock\/sector weakness than a volume-led breakdown.<\/p>\n<h3 style=\"margin:13px 0 4px;font-size:15px;\">How strong is trading participation today?<\/h3>\n<p style=\"margin:0;line-height:1.55;font-size:13px;\">Participation is moderate rather than exceptional. By 11:25 AM, cash volume was about 44% of the 20-day average full-session volume, so the move had not yet developed into an unusually high-volume sell-off.<\/p>\n<h3 style=\"margin:13px 0 4px;font-size:15px;\">What is Sun Pharma\u2019s promoter pledge?<\/h3>\n<p style=\"margin:0;line-height:1.55;font-size:13px;\">The latest available data shows 1.65% of promoter holdings pledged, up by 0.23 percentage points in the latest quarter.<\/p>\n<div style=\"font-size:11.5px;line-height:1.55;color:#606b78;border-top:1px solid #e1e7ef;padding-top:13px;margin-top:22px;\"><strong>Disclaimer:<\/strong> Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting.<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Price \u20b91,821.30 Change -2.34% High \/ Low \u20b91,860.60 \/ \u20b91,814.20 Prev. Close \u20b91,865.00 Volume 6.10L Updated 11:25 AM Key Takeaways [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"","_witty_meta_description":"","_witty_primary_phrase":"","_witty_reason_label":"","_witty_reason_confidence":"","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[1],"tags":[],"class_list":["post-1394","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=1394"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1394\/revisions"}],"predecessor-version":[{"id":1395,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1394\/revisions\/1395"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=1394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=1394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=1394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}